Adverum Biotechnologies Inc
ADVM2.380USD
+0.060+2.59%
交易中 （美東）報價延遲15分鐘
49.40M總市值
虧損本益比TTM
關於 Adverum Biotechnologies Inc 公司
Adverum Biotechnologies, Inc. 是一家臨牀階段的基因治療公司。該公司發現並開發基因治療候選產品，通過誘導治療性蛋白質的持續表達來提供持久的療效。其主要候選產品 ixoberogene soroparvovec (Ixo-vec) 是一種單次、辦公室內玻璃體內 (IVT) 注射基因治療產品，旨在提供與持續治療反應相關的長期持久的阿柏西普水平，減少治療負擔和與頻繁抗血管內皮生長因子 (VEGF) IVT 注射相關的黃斑液波動。Ixo-vec 正在開發用於治療溼性老年性黃斑變性患者。其第二個候選產品 ADVM-062 (AAV.7m8-L-opsin) 是一種基因治療候選產品，正在開發中，通過單次 IVT 注射治療患有藍錐單色性 (BCM) 的患者。該公司還正在開發早期的基因治療項目。
公司簡介
公司代碼ADVM
公司名稱Adverum Biotechnologies Inc
上市日期Jul 31, 2014
CEODr. Laurent Fischer, M.D.
員工數量155
證券類型Ordinary Share
年結日Jul 31
公司地址100 Cardinal Way
城市REDWOOD CITY
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94063
電話16506491004
網址https://adverum.com/
公司代碼ADVM
上市日期Jul 31, 2014
CEODr. Laurent Fischer, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
Ms. Linda M. Rubinstein
Ms. Linda M. Rubinstein
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. C. David Nicholson, Ph.D.
Dr. C. David Nicholson, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason L. Mitchell
Mr. Jason L. Mitchell
Chief Commercial Officer
Chief Commercial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
BML Capital Management LLC
14.64%
TCG Crossover Management, LLC
8.60%
Franklin Advisers, Inc.
8.43%
Principia Wealth Advisory, LLC
8.12%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
53.93%
持股股東
持股股東
佔比
BML Capital Management LLC
14.64%
TCG Crossover Management, LLC
8.60%
Franklin Advisers, Inc.
8.43%
Principia Wealth Advisory, LLC
8.12%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
53.93%
股東類型
持股股東
佔比
Investment Advisor
46.39%
Investment Advisor/Hedge Fund
15.91%
Individual Investor
12.20%
Private Equity
6.88%
Venture Capital
5.02%
Hedge Fund
2.57%
Research Firm
2.54%
Corporation
0.87%
Bank and Trust
0.12%
Other
7.51%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
192
19.32M
92.50%
-3.22M
2025Q1
200
18.99M
90.93%
-3.09M
2024Q4
197
18.17M
87.35%
-2.16M
2024Q3
205
18.40M
88.51%
-3.17M
2024Q2
198
18.25M
87.99%
-2.40M
2024Q1
209
17.03M
82.27%
+429.10K
2023Q4
203
6.60M
65.29%
-2.40M
2023Q3
243
6.95M
68.86%
-2.49M
2023Q2
271
6.98M
69.47%
-2.29M
2023Q1
309
6.72M
66.88%
-3.80M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BML Capital Management LLC
3.06M
14.64%
+315.21K
+11.49%
May 19, 2025
TCG Crossover Management, LLC
1.80M
8.6%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.76M
8.43%
--
--
Mar 31, 2025
Principia Wealth Advisory, LLC
1.70M
8.12%
+366.15K
+27.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.31M
6.29%
-57.92K
-4.22%
Mar 31, 2025
Stern (Augustus)
1.12M
5.35%
+1.12M
--
Oct 29, 2024
Frazier Life Sciences Management, L.P.
1.07M
5.12%
--
--
Mar 31, 2025
Rush (Ryan Bradford)
1.05M
5.03%
+1.05M
--
Dec 17, 2024
The Vanguard Group, Inc.
1.03M
4.93%
-1.76K
-0.17%
Mar 31, 2025
5AM Ventures
541.67K
2.59%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
iShares Micro-Cap ETF
佔比0.01%
Fidelity Enhanced Small Cap ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
公告日期
類型
比率
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
